

1-1-2011

Synthesis and antimicrobial activity of methoxy azachalcones and N-alkyl substituted methoxy azachalconium bromides

CANAN ALBAY

NURAN KAHRİMAN

NAGİHAN YILMAZ İSKENDER

ŞENGÜL ALPAY KARAOĞLU

NURETTİN YAYLI

Follow this and additional works at: <https://journals.tubitak.gov.tr/chem>

 Part of the [Chemistry Commons](#)

Recommended Citation

ALBAY, CANAN; KAHRİMAN, NURAN; İSKENDER, NAGİHAN YILMAZ; KARAOĞLU, ŞENGÜL ALPAY; and YAYLI, NURETTİN (2011) "Synthesis and antimicrobial activity of methoxy azachalcones and N-alkyl substituted methoxy azachalconium bromides," *Turkish Journal of Chemistry*. Vol. 35: No. 3, Article 8. <https://doi.org/10.3906/kim-1007-790>

Available at: <https://journals.tubitak.gov.tr/chem/vol35/iss3/8>

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Chemistry by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.

Synthesis and antimicrobial activity of methoxy azachalcones and N-alkyl substituted methoxy azachalconium bromides

Canan ALBAY¹, Nuran KAHRİMAN¹, Nagihan YILMAZ İSKENDER¹,
Şengül ALPAY KARAOĞLU², Nurettin YAYLI^{1,*}

¹*Department of Chemistry, Faculty of Sciences, Karadeniz Technical University,
61080, Trabzon-TURKEY
e-mail: yayli@ktu.edu.tr*

²*Department of Biology, Faculty of Arts and Sciences, Rize University, 53100, Rize-TURKEY*

Received: 12.07.2010

In this study, 18 new N-octyl, N-decyl, and N-dodecyl substituted *o*-, *m*-, and *p*-methoxy (*E*)-3- and 4-azachalcones, {4- or 3-[(1*E*)-3-(4-, 3-, or 2-methoxyphenyl)-3-oxoprop-1-en-1-yl]-1-alkyl (C_{8,10,12}) pyridinium bromides} (**1a-6a**, **1b-1b**, and **1c-6c**), and 4 new *o*-, and *m*-methoxy (*E*)-3- and 4-azachalcones (**2**, **3**, **5**, and **6**) were synthesized and tested for antimicrobial activities against *Escherichia coli*, *Yersinia pseudotuberculosis*, *Enterobacter aerogenes*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Bacillus cereus*, and *Candida albicans*. N-Alkyl substituted azachalconium bromides showed good antimicrobial activity against all tested microorganisms with minimal inhibitory concentration (MIC) values in the range of 0.42-58.7 µg/mL in most cases. Nonalkylated compounds **1-9** were not as effective as the alkylated compounds. They showed only antimicrobial activity against gram-positive bacteria and yeast in the range of 1.77-123.7 µg/mL. The optimum length of the alkyl chain for better activity is situated with 12 carbon atoms in the series of compounds **1a-c**, **2a-c**, **3a-c**, **4a-c**, **5a-c**, and **6a-c**. N-Alkyl derivatives of *m*-methoxy (*E*)-3-azachalcone (**4a-c**, **5a-c**, and **6a-c**) showed better activity in comparison to those of *o*- and *p*-methoxy (*E*)-4-azachalcones (**1a-c**, **2a-c**, and **3a-c**).

Key Words: N-Alkyl *p*-methyl-(*E*)-3- and 4-azachalconium bromides, antimicrobial activity

Introduction

A range of synthetic chalcones and azachalcones were prepared and the structure-activity relationships were explored.¹⁻⁴ Chalcones (1,3-diphenyl-2-propen-1-ones) are key precursors in the synthesis of a large array of

*Corresponding author

biologically important heterocycles (azachalcones).^{5,6} Thus, the synthesis of azachalcones has generated vast interest among organic and medicinal chemists. Chalcones and their heterocyclic analogs (azachalcones) display a wide range of biological activities, such as anticancer,⁷ antimitotic,⁸ antiinflammatory,⁹ antituberculosis,¹⁰ antimalarial,^{11,12} antileishmanial,^{13,14} nitric oxide regulation modulatory,¹⁵ cardiovascular,¹⁶ cell differentiation-inducing¹⁷ and antihyperglycemic,¹⁸ activities.

N-alkyl derivatives of azachalcones have also been synthesized by several researchers^{5,6,19–25} and were shown to possess a wide variety of biological activities, such as antiinflammatory, antimicrobial, antituberculo-static, and antibacterial potentials.^{19–33} In our previous works, nitro- and methyl-substituted (*E*)-3- and 4-azachalcones and their N-alkyl derivatives were synthesized and showed very good antimicrobial activities, especially against gram-positive bacteria.^{25–28} Many of the more active chalcone and azachalcone compounds are substituted with methoxy and/or hydroxyl groups.^{1,2} In view of the continuing interest in new antimicrobial agents, we prepared other N-alkyl(C_{8,10,12}) substituted *m*- and *p*-methoxy-(*E*)-3- and 4-azachalconium bromides in this respect. We aimed to determine the influence of the methoxy substitution, the length of the carbon chain in the N-alkyl substituent, and the position of N in the pyridyl ring on antimicrobial activity. The attempts to synthesize N-alkylated *o*-, *m*-, and *p*-methoxy (*E*)-2-azachalcones were unsuccessful. The present work deals with the synthesis, spectral characterization, and antimicrobial activity of 18 new N-alkyl substituted *m*- and *p*-methoxy (*E*)-3- and 4-azachalcones (**1a-6a**, **1b-6b**, and **1c-6c**) and 4 new *o*- and *m*-methoxy (*E*)-3- and 4-azachalcones (**2**, **3**, **5**, and **6**) (Scheme).

Experimental

General

NMR spectra were recorded on a Varian Mercury NMR at 200 MHz in CDCl₃. The mass spectral analyses were carried out on a Micromass Quattro LC-MS/MS spectrometer. The elemental analyses were performed on a LECO CHNS 932 instrument. Infrared spectra were obtained with a PerkinElmer 1600 FT-IR (4000-400 cm⁻¹) spectrophotometer. Melting points were determined by using a Thermovar apparatus fitted with a microscope and are uncorrected. UV-Vis spectral analyses were carried out on a Unicam UV2-100 spectrophotometer at 25 °C. Thin layer chromatography (TLC) was carried out on Merck precoated 60 Kieselgel F₂₅₄ analytical aluminum plates. Column chromatography studies were carried out on silica gel.

Materials and methods

o-, *m*-, and *p*-Methoxy acetophenone and 2-, 3-, and 4-pyridine carboxaldehydes were purchased from Sigma-Aldrich and Merck and were used without further purification. The analytical grade or bulk solvents used (chloroform, *n*-hexane, ethanol, methanol, acetonitrile, and diethyl ether) were distilled before use.

Synthesis of compounds 1-9

Compounds **1-9** were prepared according to the literature.^{5,18–36} See the physicochemical and ¹H- and ¹³C-NMR data of compounds **1-9** in Tables 1-3.

Table 1. Physicochemical data of compounds 1-9.

Comp.	IR (CHCl ₃ , cm ⁻¹)				Formula ^a	LC-MS (%)	Yield (%)	Mp (°C)	UV-Vis λ _{nm} (log ε)		TLC (R _f)
	C=O	-OCH ₃	=CH	-CH							
1	1664	1263	3030, 3066	2835, 2967	C ₁₅ H ₁₃ NO ₂	240 (100)	96	121-123	286 (4.4)	316 (4.3)	0.47 ^b
2	1667	1259	3022, 3071	2836, 2940	C ₁₅ H ₁₃ NO ₂	240 (048)	68	79-81	284 (4.4)	340 (3.6)	0.56 ^c
3	1663	1244	3026, 3066	2830, 2940	C ₁₅ H ₁₃ NO ₂	240 (100)	79	71-75	284 (4.2)	328 (3.5)	0.41 ^c
4	1664	1263	3038, 3071	2841, 2974	C ₁₅ H ₁₃ NO ₂	240 (100)	82	93-96	282 (4.0)	314 (4.2)	0.37 ^b
5	1665	1258	3033, 3066	2830, 2940	C ₁₅ H ₁₃ NO ₂	240 (100)	56	82-85	283 (4.3)	302 (4.4)	0.52 ^c
6	1660	1244	3028, 3077	2841, 2943	C ₁₅ H ₁₃ NO ₂	240 (100)	64	60-63	282 (4.3)	302 (4.4)	0.46 ^b
7	1661	1260	3015, 3054	2840, 2935	C ₁₅ H ₁₃ NO ₂	240 (068)	68	49-52	276 (3.5)	318 (3.9)	0.63 ^b
8	1665	1254	3020, 3066	2835, 2938	C ₁₅ H ₁₃ NO ₂	240 (100)	61	65-68	280 (4.1)	308 (4.3)	0.67 ^b
9	1660	1244	3016, 3071	2835, 2940	C ₁₅ H ₁₃ NO ₂	240 (100)	75	70-74	280 (3.7)	304 (3.9)	0.72 ^c

^aElemental analyses of compounds 1-9 for C, H, O, and N are within ±0.4% of the theoretical values.

^bEther.

^cEthyl acetate.

Table 2. ¹H-NMR (δ ppm, J Hz) data of compounds **1-9** in CDCl₃.

H No.	Compounds*								
	1	2	3	4	5	6	7	8	9
2	7.6, d, 15.6	7.5, d, 16.8	7.5, d, 16.8	7.7, d, 16.0	7.5, d, 15.6	7.4, d, 16.0	7.7, d, 15.6	7.8, d, 15.4	7.6, d, 15.6
3	7.7, d, 15.6	7.6, d, 16.8	7.6, d, 16.8	7.6, d, 16.0	7.7, d, 15.6	7.6, d, 16.0	8.1, d, 15.6	8.1, d, 15.4	7.8, d, 15.6
2'	8.0, d, 8.2	7.6, s	-	8.0, d, 8.6	7.6, s	-	8.1, d, 9.0	7.6, s	-
3'	7.0, d, 8.6	-	7.0, d, 8.2	6.9, d, 8.6	-	7.0, d, 8.6	7.0, d, 9.0	-	7.0, d, 8.6
4'	-	7.1, d, 8.0	7.5, d, 8.2	-	7.1, d, 8.0	7.4, d, 8.8	-	7.1, d, 7.8	7.4, m
5'	7.0, d, 8.6	7.3, d, 7.8	7.0, t, 7.4	6.9, d, 8.6	7.4, d, 8.2	7.0, t, 7.4	7.0, d, 9.0	7.4, t, 7.8	7.0, d, 7.6
6'	8.0, d, 8.2	7.6, d, 7.8	7.6, d, 7.8	8.0, d, 8.6	7.5, d, 8.2	7.6, d, 7.4	8.1, d, 9.0	7.7, d, 6.6	7.6, d, 8.0
2''	7.4, d, 5.4	7.4, d, 5.4	7.4, d, 5.8	8.8, s	8.8, s	8.8, s	-	-	-
3''	8.6, d, 5.0	8.6, d, 5.4	8.6, d, 6.0	-	-	-	8.7, d, 4.4	8.7, d, 4.8	8.6, d, 4.4
4''	-	-	-	8.6, d, 6.6	8.6, d, 5.4	8.6, d, 4.6	7.3, t, 6.6	7.4, d, 6.6	7.2, t, 6.6
5''	8.6, d, 5.0	8.6, d, 5.4	8.6, d, 6.0	7.3, t, 6.8	7.3, m	7.3, m	7.7, t, 6.6	7.8, t, 5.8	7.7, t, 5.8
6''	7.4, d, 5.4	7.4, d, 5.4	7.4, d, 5.8	7.9, d, 6.2	7.9, d, 6.8	7.9, d, 6.2	7.4, d, 7.8	7.5, d, 7.8	7.4, d, 7.4
-OCH ₃	3.9, s	3.8, s	3.9, s	3.8, s	3.8, s	3.9, s	3.9, s	3.9, s	3.9, s

 *Assignment based on ¹H, ¹H-¹H.

Table 3. ^{13}C -NMR (δ ppm) data of compounds **1-9** in CDCl_3 .

H No.	Compounds*								
	1	2	3	4	5	6	7	8	9
1	187.8	189.2	191.7	187.7	189.3	192.9	188.5	190.1	193.0
2	125.7	125.8	130.5	123.6	123.6	128.6	125.4	125.4	124.5
3	140.5	141.3	139.0	139.8	140.7	138.7	141.9	142.7	141.4
1'	130.2	138.6	128.2	130.6	138.9	128.5	130.7	139.1	128.8
2'	130.9	112.7	158.3	130.7	112.7	158.1	131.0	112.6	158.1
3'	113.9	159.8	111.5	113.8	159.7	111.5	113.8	159.8	111.4
4'	163.7	121.0	133.6	163.5	119.5	134.5	163.6	119.8	133.1
5'	113.9	129.6	120.7	113.8	129.5	120.7	113.8	129.6	120.5
6'	130.9	121.9	130.7	130.7	123.7	130.4	131.0	124.4	130.2
1''	142.1	141.8	142.3	130.4	130.4	130.8	153.2	153.0	153.4
2''	121.9	119.6	121.9	149.7	149.9	149.7	-	-	-
3''	150.4	150.4	150.3	-	-	-	150.0	150.1	150.0
4''	-	-	-	150.7	150.9	150.6	125.3	121.4	124.0
5''	150.4	150.4	150.3	123.4	120.9	123.6	136.9	136.9	136.6
6''	121.9	119.6	121.9	134.4	134.4	133.3	124.3	119.8	124.0
-OCH ₃	55.4	55.3	55.6	55.4	55.3	55.6	55.4	55.4	55.6

*Assignment based on APT and comparison with ACD-NMR program.

Synthesis of compounds **1a-6a**, **1b-6b**, and **1c-6c**

Compounds **1a-6a**, **1b-6b**, and **1c-6c** were prepared according to the general procedure given below. See the physicochemical and ^1H - and ^{13}C -NMR data of compounds **1a-6a** in Tables 4-8.

General procedure for synthesis of compounds **1a-6a**, **1b-6b**, and **1c-6c**

m- and *p*-Methoxy (*E*)-3- or 4-azachalcones (0.02 mol each) and *n*-bromoalkanes (1-bromooctane, 1-bromodecane, and 1-bromododecane (0.05 mol each)) in acetonitrile (30 mL) were refluxed separately for 12-24 h.²⁵ The reactions were followed and monitored by TLC. After the reactions were complete, the acetonitrile was removed using a rotary evaporator and the residues were separated by column chromatography on silica gel (30 × 2 cm, approximately 25 g each, Merck, 230-400 mesh), first with ethyl acetate (30 mL) and then with ethyl acetate-methanol (3:1, 20 mL; 3:2, 20 mL), methanol (30 mL), and finally methanol-water (4:1, 30 mL). Fractions (6-12 mL each) were collected and monitored by analytical TLC. The desired dark red amorphous solids (**1a-6a**, **1b-6b**, and **1c-6c**) were obtained from fractions 6-13 (yields are shown in Table 1).

Table 4. Physicochemical data of compounds **1a-6a**, **1b-6b**, and **1c-6c**.

Comp.	IR (CHCl ₃ , cm ⁻¹)			Formula ^a	LC MS/MS (%)				Yield (%)	Mp (°C)	UV-Vis λ _{nm} (log ε)	TLC (R _f) ^b
	C=O	OCH ₃	-CH		[M ^{(79)Br}] ⁺	[M ^{(81)Br}] ⁺	[M- ⁷⁹ Br] ⁺	[M ^{(79)Br}]-RH] ⁺				
1a	1661	1234	2926	C ₂₃ H ₃₀ BrNO ₂	431 (5)	433 (18)	352 (88)	239 (100)	63	177-180	290 (4.1)	0.16
2a	1667	1261	2927	C ₂₃ H ₃₀ BrNO ₂	431 (8)	433 (10)	352 (63)	239 (100)	83	137-140	292 (4.4)	0.18
3a	1657	1245	2927	C ₂₃ H ₃₀ BrNO ₂	431 (6)	433 (12)	352 (90)	239 (100)	88	99-101	294 (4.4)	0.13
4a	1663	1241	2928	C ₂₃ H ₃₀ BrNO ₂	431 (5)	433 (22)	352 (50)	239 (100)	39	55-58	280 (4.3)	0.15
5a	1668	1263	2928	C ₂₃ H ₃₀ BrNO ₂	431 (3)	433 (20)	352 (60)	239 (100)	46	98-101	284 (4.2)	0.16
6a	1662	1247	2927	C ₂₃ H ₃₀ BrNO ₂	431 (12)	433 (9)	352 (78)	239 (100)	65	oily	278 (4.2)	0.13
1b	1661	1234	2922	C ₂₅ H ₃₄ BrNO ₂	459 (5)	461 (11)	380 (85)	239 (100)	54	166-169	290 (4.4)	0.15
2b	1667	1262	2926	C ₂₅ H ₃₄ BrNO ₂	459 (10)	461 (35)	380 (100)	239 (78)	78	146-148	292 (4.1)	0.16
3b	1657	1246	2926	C ₂₅ H ₃₄ BrNO ₂	459 (3)	461 (10)	380 (100)	239 (65)	65	107-110	294 (4.3)	0.15
4b	1663	1241	2926	C ₂₅ H ₃₄ BrNO ₂	459 (3)	461 (2)	380 (82)	239 (100)	44	57-60	282 (4.4)	0.17
5b	1668	1263	2926	C ₂₅ H ₃₄ BrNO ₂	459 (4)	461 (8)	380 (72)	239 (100)	52	113-115	284 (4.1)	0.20
6b	1662	1247	2926	C ₂₅ H ₃₄ BrNO ₂	459 (8)	461 (5)	380 (100)	239 (100)	50	oily	276 (4.3)	0.20
1c	1661	1236	2923	C ₂₇ H ₃₈ BrNO ₂	487 (12)	489 (11)	408 (100)	239 (80)	76	170-172	288 (4.4)	0.10
2c	1666	1261	2925	C ₂₇ H ₃₈ BrNO ₂	487 (10)	489 (10)	408 (85)	239 (100)	84	128-131	294 (4.4)	0.20
3c	1660	1246	2925	C ₂₇ H ₃₈ BrNO ₂	487 (22)	489 (15)	408 (88)	239 (100)	76	115-118	292 (4.4)	0.18
4c	1663	1241	2926	C ₂₇ H ₃₈ BrNO ₂	487 (15)	489 (10)	408 (100)	239 (100)	43	61-64	280 (4.3)	0.21
5c	1668	1262	2924	C ₂₇ H ₃₈ BrNO ₂	487 (2)	489 (22)	408 (61)	239 (100)	43	106-108	284 (4.2)	0.21
6c	1662	1247	2925	C ₂₇ H ₃₈ BrNO ₂	487 (12)	489 (5)	408 (95)	239 (100)	49	oily	276 (4.3)	0.17

^aElemental analyses of compounds **1a-6a**, **1b-6b**, and **1c-6c** for C, H, O, Br, and N are within ±0.4% of the theoretical values.

^bMethanol.

Table 5. $^1\text{H-NMR}$ (δ ppm, J Hz) data of compounds **1a-6a** in CDCl_3 .

H No.	Compounds*					
	1a	2a	3a	4a	5a	6a
2	7.7, d, 15.8	7.7, d, 15.6	7.6, d, 15.8	7.7, d, 15.8	7.7, d, 15.8	7.7, d, 15.8
3	8.3, d, 15.8	8.3, d, 15.6	7.9, d, 15.8	8.6, d, 15.8	8.5, d, 15.8	7.9, d, 15.8
2'	8.2, d, 9.0	7.6, s	-	8.4, d, 8.8	7.7, s	-
3'	7.0, d, 9.0	-	7.0, d, 9.0	7.0, d, 8.8	-	7.0, d, 8.4
4'	-	7.8, d, 7.8	7.6, t, 8.4	-	7.1, t, 8.0	7.5, t, 8.4
5'	7.0, d, 9.0	7.4, t, 8.0	7.1, t, 8.4	7.0, d, 8.8	7.4, t, 8.0	7.0, t, 8.4
6'	8.2, d, 9.0	7.2, t, 8.0	7.5, t, 8.4	8.4, d, 8.8	7.9, d, 7.8	7.7, d, 8.2
2''	8.5, d, 6.4	8.5, d, 6.8	8.2, d, 6.4	10.5, s	10.5, s	10.0, s
3''	9.4, d, 6.4	9.3, d, 6.8	9.5, d, 6.4	-	-	-
4''	-	-	-	9.1, d, 6.0	9.2, d, 5.6	9.4, d, 5.8
5''	9.4, d, 6.4	9.3, d, 6.8	9.5, d, 6.4	8.1, t, 7.0	8.2, t, 6.4	8.3, t, 6.4
6''	8.5, d, 6.4	8.5, d, 6.8	8.2, d, 6.4	8.7, d, 6.8	8.7, d, 8.0	8.7, d, 7.6
NCH ₂ -	4.9, t, 7.0	4.9, t, 7.4	5.0, t, 7.4	5.1, t, 7.4	5.0, t, 7.4	5.1, t, 7.4
-(CH ₂) ₆ -	2.0, m, 2H 1.3, m, 10H	2.0, m, 2H 1.3, m, 10H	2.0, m, 2H 1.3, m, 10H	2.1, m, 2H 1.3, m, 10H	2.1, m, 2H 1.3, m, 10H	2.1, m, 2H, 1.3, m, 10H
-CH ₃	0.8, t, 6.6	0.9, t, 7.0	0.9, t, 6.2	0.8, t, 6.8	0.8, t, 7.2	0.8, t, 6.8
-OCH ₃	3.9, s	3.9, s	4.0, s	3.9, s	3.9, s	4.0, s

*Assignment based on ^1H , $^1\text{H-}^1\text{H}$ COSY, and comparison with ACD-NMR program.**Table 6.** $^1\text{H-NMR}$ (δ ppm, J Hz) data of compounds **1b-6b** in CDCl_3 .

H No.	Compounds*					
	1b	2b	3b	4b	5b	6b
2	7.7, d, 15.4	7.7, d, 15.4	7.6, d, 15.8	7.7, d, 15.8	7.7, d, 15.8	7.7, d, 15.8
3	8.4, d, 15.4	8.3, d, 15.4	7.9, d, 15.8	8.7, d, 15.8	8.5, d, 15.8	7.9, d, 15.8
2'	8.2, d, 8.8	7.6, s	-	8.4, d, 9.0	7.7, s	-
3'	7.0, d, 8.8	-	7.0, d, 8.2	7.0, d, 9.0	-	7.0, d, 8.0
4'	-	7.2, d, 8.2	7.6, t, 8.2	-	7.1, d, 8.0	7.5, t, 8.0
5'	7.0, d, 8.8	7.4, t, 8.0	7.1, t, 8.0	7.0, d, 9.0	7.4, t, 8.0	7.0, t, 8.0
6'	8.2, d, 8.8	7.8, d, 7.8	7.8, d, 8.0	8.4, d, 9.0	8.0, d, 7.8	7.7, d, 7.8
2''	8.5, d, 6.8	8.5, d, 6.4	8.2, d, 6.8	10.6, s	10.4, s	9.9, s
3''	9.4, d, 6.8	9.4, d, 6.4	9.5, d, 6.8	-	-	-
4''	-	-	-	9.1, d, 5.8	9.2, d, 6.2	9.4, d, 5.6
5''	9.4, d, 6.8	9.4, d, 6.4	9.5, d, 6.8	8.1, t, 6.2	8.1, t, 6.4	8.3, t, 6.4
6''	8.5, d, 6.8	8.5, d, 6.4	8.2, d, 6.8	8.7, d, 8.4	8.7, d, 8.0	8.7, d, 8.2
NCH ₂ -	4.9, t, 7.0	4.9, t, 7.8	5.0, t, 7.4	5.1, t, 7.4	5.1, t, 7.4	5.1, t, 7.4
-(CH ₂) ₈ -	2.0, m, 2H 1.3, m, 14H	2.1, m, 2H 1.3, m, 14H	2.0, m, 2H 1.3, m, 14H	2.2, m, 2H 1.2, m, 14H	2.1, m, 2H 1.3, m, 14H	2.1, m, 2H, 1.3, m, 14H
-CH ₃	0.9, t, 6.6	0.9, t, 6.4	0.9, t, 6.8	0.9, t, 6.8	0.9, t, 7.0	0.9, t, 6.8
-OCH ₃	3.9, s	3.9, s	4.0, s	3.9, s	3.9, s	4.0, s

*Assignment based on ^1H , $^1\text{H-}^1\text{H}$ COSY, and comparison with ACD-NMR program.

Table 7. $^1\text{H-NMR}$ (δ ppm, J Hz) data of compounds **1c-6c** in CDCl_3 .

H No.	Compounds*					
	1c	2c	3c	4c	5c	6c
2	7.7, d, 15.8	7.7, d, 15.4	7.6, d, 15.8	7.6, d, 15.8	7.7, d, 15.8	7.6, d, 16.2
3	8.3, d, 15.8	8.2, d, 15.4	7.9, d, 15.8	8.7, d, 15.8	8.5, d, 15.8	7.9, d, 16.2
2'	8.2, d, 8.8	7.6, s	-	8.4, d, 8.0	7.7, s	-
3'	7.0, d, 8.8	-	7.0, d, 8.8	7.0, d, 8.0	-	7.0, d, 7.8
4'	-	7.8, d, 7.8	7.6, t, 8.4	-	7.1, d, 8.4	7.5, t, 8.4
5'	7.0, d, 8.8	7.4, t, 8.0	7.1, t, 8.6	7.0, d, 8.0	7.4, t, 8.0	7.0, t, 7.8
6'	8.2, d, 8.8	7.2, t, 8.0	7.8, d, 8.4	8.4, d, 8.0	7.9, d, 7.8	7.7, d, 7.8
2''	8.5, d, 6.8	8.5, d, 6.8	8.2, d, 6.4	10.6, s	10.5, s	9.9, s
3''	9.3, d, 6.8	9.3, d, 6.8	9.5, d, 6.4	-	-	-
4''	-	-	-	8.9, d, 5.8	9.2, d, 6.0	9.4, d, 6.0
5''	9.3, d, 6.8	9.3, d, 6.8	9.5, d, 6.4	8.0, t, 6.2	8.1, t, 6.2	8.3, d, 6.0
6''	8.5, d, 6.8	8.5, d, 6.8	8.2, d, 6.4	8.6, d, 8.8	8.7, d, 8.0	8.7, d, 8.0
NCH ₂ -	4.9, t, 7.2	4.9, t, 7.4	5.0, t, 7.4	5.1, t, 7.4	5.1, t, 7.0	5.1, t, 7.4
-(CH ₂) ₁₀ -	2.1, m, 2H 1.2, m, 18H	2.0, m, 2H 1.3, m, 18H	2.0, m, 2H 1.3, m, 18H	2.2, m, 2H 1.3, m, 18H	2.1, m, 2H 1.3, m, 18H	2.1, m, 2H 1.3, m, 18H
-CH ₃	0.9, t, J 6.6	0.9, t, 7.0	0.9, t, 6.8	0.9, t, 6.8	0.9, t, 7.2	0.9, t, 6.8
-OCH ₃	3.9, s	3.9, s	4.0, s	3.8, s	3.9, s	4.0, s

*Assignment based on ^1H , $^1\text{H-}^1\text{H}$ COSY, and comparison with ACD-NMR program.

Antimicrobial activity assessment

All test microorganisms were obtained from the Refik Saydam National Public Health Agency (Ankara, Turkey) and were as follows: *Escherichia coli* ATCC 25922, *Yersinia pseudotuberculosis* ATCC 911, *Enterobacter aerogenes* ATCC 13048, *Pseudomonas aeruginosa* ATCC 27853, *Staphylococcus aureus* ATCC 25923, *Enterococcus faecalis* ATCC 29212, *Bacillus cereus* 702 Roma, and *Candida albicans* ATCC 60193. All of the newly synthesized compounds were weighed and dissolved in dimethylsulphoxide (DMSO) to prepare an extract stock solution of milligrams per milliliter.

The antimicrobial effects of the substances were tested quantitatively by the microdilution technique in Mueller Hinton broth. The minimal inhibition concentration (MIC) of the extracts was also determined using a 2-fold dilution method.³⁷ The antibacterial and antifungal assays were performed in Mueller-Hinton broth (MH) (Difco, Detroit, MI) at pH 7.3 and a buffered yeast nitrogen base (Difco) at pH 7.0, respectively. The MIC was defined as the lowest concentration that showed no growth. Ampicillin (1.2 mg/mL) and fluconazole (2 mg/mL) were used as standard antibacterial and antifungal drugs, respectively. Dimethylsulphoxide (DMSO) was used as the solvent control. The results are shown in Table 9.

Table 8. ¹³C-NMR (δ ppm) data of compounds **1a-6a**, **1b-6b**, and **1c-6c** in CDCl₃.

++	Compounds																	
	1a	2a	3a	4a	5a	6a	1b	2b	3b	4b	5b	6b	1c	2c	3c	4c	5c	6c
1	186.7	188.6	189.8	186.9	188.4	190.4	186.7	188.2	189.8	186.9	188.6	190.3	186.6	188.2	189.7	186.9	188.4	190.3
2	133.4	133.3	133.5	130.4	129.8	128.7	133.4	133.1	133.5	130.3	130.2	128.7	133.6	133.1	133.4	130.7	129.9	128.7
3	135.5	136.5	137.1	133.8	134.9	132.8	135.5	136.2	137.0	133.7	134.8	132.6	135.3	136.1	137.2	133.6	134.8	132.6
1'	129.5	138.0	127.1	129.6	137.9	127.3	129.5	137.7	127.0	129.6	138.0	127.3	129.5	137.7	127.1	129.7	137.9	127.3
2'	131.9	113.0	159.0	132.2	112.8	158.8	131.9	112.7	158.9	132.1	112.9	158.8	131.9	112.7	159.1	132.3	112.8	158.7
3'	114.3	160.3	111.8	114.2	159.8	111.8	114.3	160.0	111.7	114.1	160.1	111.7	114.4	160.0	111.8	114.3	159.9	111.7
4'	164.4	121.3	134.9	164.2	120.6	134.3	164.4	121.1	134.9	164.1	120.9	134.4	164.5	121.1	135.0	164.3	120.7	134.4
5'	114.3	130.3	121.0	114.2	129.7	120.7	114.3	130.1	121.0	114.1	130.0	120.7	114.4	130.1	121.1	114.3	129.8	120.7
6'	131.9	127.1	131.1	132.2	122.3	133.6	131.9	126.7	131.0	132.1	122.5	133.6	131.9	126.7	131.1	132.3	122.3	133.6
1''	151.2	151.1	151.3	136.4	135.9	136.0	151.2	150.9	151.3	136.4	136.1	136.0	151.4	150.9	151.4	136.7	135.9	136.0
2''	126.8	122.3	126.1	144.3	144.2	144.6	126.8	122.1	126.1	145.0	144.5	144.6	126.7	122.1	126.1	144.4	144.3	144.6
3''	145.1	145.4	145.3	-	-	-	145.0	145.1	145.3	-	-	-	144.9	145.1	145.3	-	-	-
4''	-	-	-	144.2	144.0	144.2	-	-	-	144.1	144.2	144.1	-	-	-	144.2	144.0	144.1
5''	145.1	145.4	145.3	128.1	128.3	130.7	145.0	145.1	145.3	128.1	128.3	130.8	144.9	145.1	145.3	127.9	128.3	130.8
6''	126.8	122.3	126.1	143.3	144.0	142.5	126.8	122.1	126.1	143.3	143.9	142.5	126.7	122.1	126.1	142.9	143.8	142.5
NCH ₂ -	61.7	62.0	61.5	62.0	61.9	62.0	61.7	61.8	61.4	61.9	62.1	62.0	61.9	61.8	61.6	62.1	61.9	61.9
-(CH ₂) _n -	31.9	32.1	31.9	32.1	31.9	31.8	31.8	31.8	31.8	32.1	32.1	31.9	31.9	31.8	31.9	32.2	32.0	31.9
	31.6	31.9	31.6	31.7	31.5	31.4	29.4	29.4	31.7	31.7	31.8	31.7	29.6	29.5	31.8	31.9	31.8	31.7
	29.0	29.2	28.9	29.0	28.9	28.9	29.2	29.3	29.3	29.4	29.5	29.3	29.5	29.5	29.5	29.6	29.5	29.4
	26.1	26.3	26.0	26.1	26.0	25.9	29.1	29.2	29.2	29.6	29.4	29.2	29.3	29.3	29.4	29.5	29.4	29.4
	22.6	22.8	22.5	22.7	22.4	22.4	26.1	29.0	29.1	29.1	29.2	29.1	29.1	29.0	29.3	29.3	29.3	29.2
							22.7	26.1	29.0	29.0	29.1	29.0	26.1	26.1	29.2	26.1	29.0	29.2
								22.6	26.0	26.0	26.1	25.9	22.7	22.6	26.1	26.1	29.0	29.0
									22.5	22.6	22.6	22.5			22.6	22.7	26.0	25.9
																	22.6	22.5
-CH ₃	14.1	14.3	14.0	14.1	13.9	13.9	14.1	14.1	14.0	14.0	14.1	14.0	14.1	14.1	14.1	14.1	14.0	14.0
-OCH ₃	55.7	56.0	56.1	55.6	55.8	56.1	55.7	55.7	56.0	55.5	56.0	56.1	55.7	55.7	56.1	55.6	55.8	56.1

* Assignment based on APT and comparison with ACD-NMR program; n: 6, 8, 10.


Table 9. Minimum inhibitory concentrations (MIC, $\mu\text{g}/\text{mL}$) of compounds **1-9**, **1a-6a**, **1b-6b**, and **1c-6c**.

Comp.	Stock conc. ($\mu\text{g}/100 \mu\text{L}$)	Minimal inhibition concentration values ($\mu\text{g}/\text{mL}$)							
		<i>Ec</i> (-)	<i>Yp</i> (-)	<i>En</i> (-)	<i>Pa</i> (-)	<i>Sa</i> (+)	<i>Ef</i> (+)	<i>Bc</i> (+)	<i>Ca</i>
1	9900	> 495	> 495	> 495	> 495	61.9	123.7	61.9	15.5
2	11,300	> 283	> 283	> 283	> 283	2.20	8.83	8.83	17.6
3	9900	> 247	> 247	> 247	> 247	7.72	30.9	15.5	15.5
4	10,400	> 260	> 260	> 260	> 260	65.0	30.0	65.0	32.5
5	12,100	> 303	> 303	> 303	> 303	4.72	37.8	9.45	37.8
6	9600	> 240	> 240	> 240	> 240	30.0	120	30.0	15.0
7	10,200	> 510	> 510	> 510	> 260	7.96	31.8	15.9	15.9
8	9100	> 227	> 227	> 227	> 227	1.77	14.7	7.10	< 7.10
9	9100	> 227	> 227	> 227	> 227	7.10	28.4	14.2	7.10
1a	8600	6.72	13.5	26.8	53.7	0.42	1.67	1.67	< 6.72
1b	8800	3.44	3.44	3.44	13.7	0.42	0.42	0.42	< 6.87
1c	9300	> 233	> 233	> 233	116.2	0.45	0.45	0.45	58.1
2a	9200	3.59	7.18	14.4	28.7	0.45	0.90	0.90	< 7.18
2b	9600	0.94	3.75	3.75	15.0	< 0.47	< 0.47	< 0.47	< 7.50
2c	9800	0.47	0.96	0.45	7.65	< 0.47	< 0.47	< 0.47	< 7.65
3a	1040	8.12	16.2	16.2	32.5	0.50	1.01	2.03	< 8.12
3b	8700	3.40	6.80	3.40	13.6	< 0.43	< 0.43	< 0.43	< 6.80
3c	9800	0.96	3.82	1.92	3.82	< 0.46	< 0.46	< 0.46	< 7.65
4a	9300	3.63	7.26	29.0	29.0	0.45	0.90	0.90	< 7.26
4b	8800	0.84	3.44	6.8	13.7	< 0.44	< 0.44	< 0.44	< 6.8
4c	9900	0.48	1.93	0.96	7.73	< 0.48	< 0.48	< 0.48	< 7.73
5a	9500	3.71	7.42	7.42	14.8	< 0.46	< 0.46	< 0.46	< 7.42
5b	9600	1.87	7.50	3.75	7.50	< 0.46	< 0.46	< 0.46	< 7.50
5c	8700	1.70	3.40	1.70	13.8	< 0.43	< 0.43	< 0.43	< 6.80
6a	9400	7.34	14.7	14.7	58.7	< 0.45	< 0.45	< 0.45	< 7.34
6b	9400	0.90	3.67	1.83	3.67	< 0.45	< 0.45	< 0.45	< 7.34
6c	9300	0.90	1.81	1.81	14.5	< 0.45	< 0.45	< 0.45	< 7.25
Amp.	1200	8	32	> 64	> 128	2	2	< 1	
Flu.	2000								< 8

a: C₈, b: C₁₀, c: C₁₂; *Ec*: *Escherichia coli*, *Yp*: *Yersinia pseudotuberculosis*, *En*: *Enterobacter aerogenes*, *Pa*: *Pseudomonas aeruginosa*, *Sa*: *Staphylococcus aureus*, *Ef*: *Enterococcus faecalis*, *Bc*: *Bacillus cereus* 702 Roma, *Ca*: *Candida albicans*, Amp: ampicillin, Flu: fluconazole.

Results and discussion

The convenient approach for the synthesis of *o*-, *m*-, and *p*-methoxy (*E*)-2-, -3-, and 4-azachalcones (**1-9**) involves the Claisen-Schmidt condensation of methoxy-substituted aryl methyl ketones with pyridine carboxaldehydes with 3 equivalents of Na₂CO₃ solution (EtOH, 95%), which yields the *trans* isomer of the corresponding α,β -unsaturated ($J = 15.4/16.8$ Hz, respectively) compounds (**1-9**) (Scheme, Tables 2-3).^{5,25-28}



Scheme

N-alkyl derivatives of *m*- and *p*-methoxy (*E*)-3- or 4-azachalcones were synthesized from the corresponding azachalcones with n-bromoalkanes (1-bromooctane, 1-bromodecane, and 1-bromododecane) in acetonitrile

solution by reflux.^{19,20,25–27} In the ¹H-NMR spectra of **1a-6a**, **1b-6b**, and **1c-6c**, the characteristic -CH₂- signal of the N-alkyl groups was exhibited at δ 4.9-5.1 ppm (2H, t, *J* = 7.0-7.4 Hz) (Tables 5-7) due to pyridinium salt.^{19,20,25}

N-Alkyl derivatives of azachalcones attract widespread interest because many of them have exhibited a wide variety of biological activities.^{25–33} All of the synthesized compounds (**1-9**, **1a-6a**, **1b-6b**, and **1c-6c**) were characterized on the basis of spectral data analyses (¹H-NMR, ¹³C-NMR, APT, ¹H-¹H COSY-NMR, ACD-NMR, FT-IR, UV, LC-MS/MS, and elemental analysis), whose results were in agreement with the proposed structures (Tables 1-8). The LC mass spectra of **1a-6a**, **1b-6b**, and **1c-6c** exhibited molecular ion peaks for [M(⁷⁹Br)]⁺ and [M(⁸¹Br)]⁺, and the base ion peaks were [M(⁷⁹Br)-79]⁺ and [M(⁸¹Br)-81]⁺ with other fragment ions such as [M(⁷⁹Br)-R]⁺ and [M(⁸¹Br)-R]⁺ (Table 4).

The antimicrobial activity of compounds **1-9**, **1a-6a**, **1b-6b**, and **1c-6c** was determined against *E. coli*, *Y. pseudotuberculosis*, *E. aerogenes*, *P. aeruginosa*, *S. aureus*, *E. faecalis*, *B. cereus*, and *C. albicans* (Table 9). The activities of compounds **1-9**, **1a-6a**, **1b-6b**, and **1c-6c** were investigated by the dilution method.³⁷ Some compounds showed from slight to pronounced antimicrobial activity against gram-positive and gram-negative bacteria. Nonalkylated compounds **1-9** were not as effective as the alkylated compounds with 8, 10, or 12 C alkyl groups (**1a-6a**, **1b-6b**, and **1c-6c**). The N-alkyl derivatives of compounds **1-9** were more active against the gram-positive bacteria (*S. aureus*, *E. faecalis*, and *B. cereus*) in the range of 0.42-2.03 μg/mL compared to the gram-negative bacteria (*E. coli*, *Y. pseudotuberculosis*, *E. aerogenes*, and *P. aeruginosa*) in the range of 0.47-233 μg/mL. *o*-, *m*-, and *p*-Methoxy substituted 3-azachalcones displayed better activity against gram-negative bacteria in the range of 0.48-58.7 μg/mL compared to *o*-, *m*-, and *p*-methoxy substituted 4-azachalcones in the range of 0.47-233 μg/mL. *m*-Methoxy 4- and 3-azachalcones showed better activity against *E. coli*, *Y. pseudotuberculosis*, *E. aerogenes*, and *P. aeruginosa* in the ranges of 0.47-28.7 and 1.70-14.8 μg/mL, as opposed to *p*-methoxy 4- and 3-azachalcones (3.44-233 and 0.48-29.0 μg/mL) and *o*-methoxy 4- and 3-azachalcones (0.96-32.5 and 0.90-58.7 μg/mL), respectively. Our previous works and research by Nowakowska et al. have shown a similar trend in activity with respect to bacterial type with methyl-, nitro-, and hydroxy-substituted and unsubstituted N-alkyl derivatives of azachalcones.^{20,26–31} The antimicrobial activity increased as the length of the alkyl substitution increased from 8 to 12, and similar results have been observed in the literature for N-bromoalkyl derivatives of azachalcones.^{20,26–31} The solvent control DMSO showed no inhibition effect on any test microorganisms.

Acknowledgements

This study was supported by grants from Karadeniz Technical University (KTÜ) and the Scientific and Technological Research Council of Turkey (TÜBİTAK).

References

1. Liu, M.; Wilairat, P.; Croft, S. L.; Tan, A. L. C.; Go, M. L. *Bioorgan. Med. Chem.* **2003**, *11*, 2729-2738.
2. Boeck, P.; Falcao, C. A. B.; Leal, P. C.; Yunes, R. A.; Cechinel, F. V.; Torres-Santos, E. C.; Rossi-Bergmann, B. *Bioorgan. Med. Chem.* **2006**, *14*, 1538-1545.

3. Dominguez, J. N.; Leon, C.; Rodrigues, J.; Gamboa de Dominguez, N.; Gut, J.; Rosenthal, P. J. *J. Med. Chem.* **2005**, *48*, 3654-3658.
4. Li, R.; Kenyon, G. L.; Cohen, F. E.; Chen, X.; Gong, B.; Dominguez, J. N.; Davidson, E.; Kurzban, G.; Miller, R. E.; Nuzum, E. O.; Rosenthal, P. J.; McKerrow, J. H. *J. Med. Chem.* **1995**, *38*, 5031-5037.
5. Dhar, D. N. (Ed.) *The Chemistry of Chalcones and Related Compounds*, Wiley, New York, 1981, p. 214.
6. Agrawal, P. K.; Bansal, M. C. In *Carbon-13 NMR of Flavonoids*; Agrawal, P. K., Ed.; Elsevier, New York, 1989, pp. 365-431.
7. Bois, F.; Beney, C.; Boumendjel, A.; Mariotte, A. M.; Conseil, G.; Di Pietro, A. J. *J. Med. Chem.* **1998**, *41*, 4161-4164.
8. Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1051-1056.
9. Hsieh, H. K.; Tsao, L. T.; Wang, J. P. *J. Pharm. Pharmacol.* **2000**, *52*, 163-171.
10. Lin, L. M.; Zhou, Y.; Flavin, M. T.; Zhou, L. M.; Nie, W.; Chen, F.C. *Bioorgan. Med. Chem.* **2002**, *10*, 2795-2802.
11. Dominguez, J. N.; Charris, J. E.; Lobo, G.; Gamboa de Dominguez, N.; Moreno, M. M.; Riggione, F.; Sanchez, E.; Olson, J.; Rosenthal, P. J. *Eur. J. Med. Chem.* **2001**, *36*, 555-560.
12. Ram, V. J.; Saxena, A. S.; Srivastava, S.; Chandra, S. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2159-2161.
13. Zhai, L.; Chen, M.; Blom, J.; Theander, T. G.; Christensen, S. B.; Kharazmi, A. *J. Antimicrob. Chemoth.* **1999**, *43*, 793-803.
14. Torres-Santos, E. C.; Rodrigues, J. M. Jr.; Moreira, D. L.; Kaplan, M. A. C.; Rossi-Bergmann, B. *Antimicrob. Agents Ch.* **1999**, *43*, 1776-1778.
15. Herencia, F.; Ferrandiz, M. L.; Ubeda, A.; Guillen, I.; Dominguez, J. N.; Charris, J. E.; Lobo, G. M.; Alcaraz, M. J. *Free Radical Bio. Med.* **2001**, *30*, 43-50.
16. Furman, C.; Lebeau, J.; Fruchart, J. C.; Bernier, J. L.; Duriez, P.; Cotelle, N.; Teissier, E. *J. Biochem. Mol. Toxicol.* **2001**, *15*, 270-278.
17. Park, E. J.; Park, R.; Lee, J. S.; Kim, J. *Planta Med.* **1998**, *64*, 464-466.
18. Satyanarayana, M.; Tiwari, P.; Tripathi, B. K.; Srivastava, A. K.; Pratap, R. *Bioorgan. Med. Chem.* **2004**, *12*, 883-889.
19. Nowakowska, Z.; Wyrzykiewicz, E.; Kedzia, B. *Il Farmaco* **2001**, *56*, 325-329.
20. Nowakowska, Z.; Wyrzykiewicz, E.; Kedzia, B. *Il Farmaco* **2002**, *57*, 657-661.
21. Nerya, O.; Musa, R.; Khatib, S.; Tamir, S.; Vaya, J. *Phytochemistry* **2004**, *65*, 1389-1395.
22. Ishitsuka, H.; Ohasawa, C.; Ohiwa, T.; Umeda, T.; Suhara, Y. *Antimicrob. Agents Ch.* **1982**, *22*, 611-616.
23. Nowakowska, Z. *Magn. Reson. Chem.* **2000**, *38*, 382-383.
24. Jovanovi, B. Z.; Vukovi, M. M.; Marinkovi, A. D.; Csanádi, J. *J. Mol. Struct.* **1999**, *482-483*, 371-374.
25. Yaylı, N.; Mısır, G.; Yaylı, N.; Yaşar, A.; Demir, E.; Demirbağ, Z. *Turk. J. Chem.* **2010**, *34*, 219-228.
26. Yaylı, N.; Üçüncü, O.; Yaşar, A.; Küçük, M.; Yaylı, N.; Akyüz, E.; Karaoğlu, Ş. A. *Turk. J. Chem.* **2006**, *30*, 505-514.
27. Yaylı, N.; Küçük, M.; Üçüncü, O.; Yaşar, A.; Yaylı, N.; Karaoğlu, Ş. A. *J. Photochem. Photobiol. A: Chem.* **2007**, *188*, 161-168.

28. Usta, A.; Yaşar, A.; Yılmaz, N.; Güleç, C.; Yaylı, N.; Karaoğlu, Ş. A.; Yaylı, N. *Helv. Chim. Acta* **2007**, *90*, 1482-1490.
29. Yaylı, N.; Yaşar, A.; Üçüncü, O.; Sivrikaya, S. Ö.; Güleç, C.; Küçük, M.; Abbasov, R. *J. Photochem. Photobiol. A: Chem.* **2005**, *171*, 291-298.
30. Yaylı, N.; Üçüncü, O.; Yaşar, A.; Gök, Y.; Küçük, M.; Kolaylı, S. *Turk. J. Chem.* **2004**, *28*, 515-521.
31. Yaylı, N.; Üçüncü, O.; Yaşar, A.; Küçük, M.; Yaylı, N.; Burnaz, N. A.; Karaoğlu, Ş. A.; Küçük, M. *J. Photochem. Photobiol. A: Chem.* **2009**, *203*, 85-91.
32. Edwards, M. L.; Stemerick, D. M.; Sabol, J. S.; Diekema, K. A.; Dinerstein, R. J. *J. Med. Chem.* **1994**, *37*, 4357-4362.
33. Zamocka, J. *Pharmazie* **1993**, *48*, 857-859.
34. Bhagat, S.; Sharma, R.; Sawant, D. M.; Sharma, L.; Chakraborti, A. K. *J. Mol. Catal. A: Chem.* **2006**, *244*, 20-24.
35. Gutteridge, C. E.; Vo, J. V.; Tillett, C. B.; Vigilante, J. A.; Dettmer, J. R.; Patterson, S. L.; Werbovets, K. A.; Capers, J.; Nichols, D. A.; Bhattacharjee, A. K.; Gerena, L. *Med. Chem.* **2007**, *3*, 115-119.
36. Lin, Y. M.; Zhou, Y.; Flavin, M. T.; Zhou, L. M.; Nie, W.; Chen, F. C. *Bioorgan. Med. Chem.* **2002**, *10*, 2795-2802.
37. *NCCLS Document M7-A313 (25)*, National Committee for Clinical Laboratory Standards, Villanova, PA, USA, 1993.